TB Alliance Annual Report 2022: Lighting the Path
TB remains the leading cause of infectious disease death – killing about 1.6 million people in 2021 alone.
The TB pandemic won’t end without innovative approaches to developing new tools to prevent, diagnose, and treat the disease, coupled with a commitment to universal access putting new tools into the hands of all who need them around the world.
The World Health Organization (WHO) updated its treatment guidelines for drug-resistant TB, allowing for nearly all DR-TB patients globally to receive short, six-month, all-oral regimens.
A new study found that the BPaL/BPaLM treatment regimens could save governments up to US$740 million annually
TB Alliance fostered a new access partnership to help pave the way for expanded access to shorter, more effective, treatment regimens for DR-TB patients globally.
TB Alliance’s mission cannot end until all people with TB have access to new treatments.
To date 50 countries have procured the six-month, all-oral BPaL regimen to treat over
7,000 people with drug-resistant TB.
TB Alliance is always seeking innovative ways to advance the fight to end TB – whether through work in consortia, open-source drug development, or our Community Engagement program.
We are funded by 19 organizations and partners from 11 countries.View our donors
As we expand access to the presently available improved treatments, we are equally committed to finding the next compounds and regimens that will have a profound impact on the TB pandemic. Without new partnerships and relentless innovation, the world’s most difficult global health problems will continue to go unsolved.